Cstone Pharmaceuticals And Jiangsu Hengrui Pharmaceuticals Announce Strategic Partnership And Exclusive Licensing Agreement On Anti-Ctla-4 Monoclonal Antibody Cs1002 In Greater China

Cstone Pharmaceuticals, A Leading Biopharmaceutical Company Focused On The Research, Development, And Commercialization Of Innovative Immuno-Oncology Therapies And Precision Medicines, And Jiangsu Hengrui Pharmaceuticals Today Announced A Strategic Partnership And Exclusive Licensing Agreement On Anti-Ctla-4 Mab Cs1002 In The Greater China Region. This Strategic Partnership Marks Another Milestone In Cstone'S Mission To Introduce Innovative Oncology Therapies In China After The Commercial Launch Of Two First-In-Class Drugs This Year.Under The Terms Of The Agreement, Cstone Will Be Eligible For An Upfront Payment And Potential Milestone Payments Up To $200 Mn In Addition To Double-Digit Royalties. Hengrui Will Obtain The Exclusive Rights For Research, Development, Registration, Manufacturing, And Commercialization Of Anti-Ctla-4 Mab Cs1002 In Greater China. Cstone Will Retain The Rights To Develop And Commercialize Of Cs1002 Outside Of Greater China.Cytotoxic T Lymphocyte Associated Antigen 4 (Ctla-4) Is One Of The Few Clinically Validated Targets For Io Combination Therapies. There Is Only One Anti-Ctla-4 Monoclonal Antibody Approved Globally, And It Is Also Approved In China. According To Evaluatepharma, The Annual Global Revenue Of The Product In 2020 Was Approximately $1.69 Billion. Cs1002 Is An Investigational Anti-Ctla-4 Monoclonal Antibody Being Developed By Cstone Currently In Clinical Development. Results From The Ongoing Ph1A/1B Study Showed That Differentiated Dosing Schedules Of Cs1002 In Combination With Cs1003 (Anti-Pd-1) Were Well-Tolerated And Demonstrated Very Encouraging Efficacy In Anti-Pd-(L)1-Refractory Melanoma, Anti-Pd-(L)1-Refractory Hepatocellular Carcinoma, And Anti-Pd-(L)1-Na

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!